Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Tuesday, the FDA approved Amgen Inc AMGN Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s AZN Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also …